2026 FIRST-QUARTER RESULTS

Presentation for investors, analysts and media

Basel, 29 April 2026

straumanngroup

DISCLAIMER

This presentation contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan,“ "goal," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group’s control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this presentation. Accordingly, you should not rely on any forward-looking statements contained in this presentation. Important factors that could cause the Group’s expectations regarding future results, performance or achievements to differ materially from those expressed in a forward-looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this presentation as of the date it is given and does not undertake any obligation to update any statements as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

AGENDA

1	Performance overview	Guillaume Daniellot
2	Financial performance	Isabelle Wege
3	Strategy update	Guillaume Daniellot
4	2026 outlook	Guillaume Daniellot
5	Q&A	Guillaume Daniellot & Isabelle Wege

1

Q1 PERFORMANCE OVERVIEW

– GUILLAUME DANIELLOT, GROUP CEO –

STRONG START INTO THE YEAR

Continuous market share gains

First quarter revenue in CHF	Organic revenue growth[1]	Regional performance
673 M	**7.1 %**	**NORTH AMERICA**
Winning share in all key market segments	or -1.2% in CHF	Growth across all businesses

Implantology	Orthodontics	Outlook 2026[2]
EXPANDING LEADERSHIP	**TRANSFORMATION IN FULL SWING**	**HIGH-SINGLE DIGIT ORGANIC REVENUE GROWTH**
Strong execution with iEXCEL, strengthening education with AOMI launch	Smartee technology and production transition completed	with 30 to 60 basis points improvement of the core EBIT margin at constant 2025 currency rates

[1] Excluding FX and M&A effects [2] Barring unforeseen events
[2] Barring unforeseen events

straumanngroup

SOLID GROWTH ACROSS REGIONS WITH VARIED MARKET DYNAMICS

NAM

Q1	7.7%
Q1 25	1.8%

EMEA

Q1	7.8%
Q1 25	10.0%



GROUP

Q1	7.1%
Q1 25	11.0%

LATAM

Q1	19.5%
Q1 25	18.8%

APAC

Q1	0.5%
Q1 25	23.0%

* % of Q1 2026 Group total revenue

2

Q1 FINANCIAL PERFORMANCE

– ISABELLE WEGE, GROUP CFO –

STRONG RESULTS WITH CONSIDERABLE FX HEADWINDS

Revenue development breakdown (in CHF million, rounded)





straumanngroup

OPERATIONAL INVESTMENTS DRIVING EFFICIENCY

New Shanghai Campus fully operational

Operational improvements in Villeret, Switzerland



ClearCorrect production scaled with Smartee



Neodent, expanding global footprint with 3rd production

- Shanghai campus fully ramped up, supporting cost efficiency and reducing FX exposure
- Ongoing optimization of the global manufacturing network, driven by automation investment and a continued improvement mindset
- Clear aligner production fully transitioned to Smartee for EMEA and APAC
- Latest geopolitical turbulence with limited impact

straumanngroup

3

STRATEGY UPDATE

– GUILLAUME DANIELLOT, GROUP CEO –

14% MARKET SHARE IN A LARGE AND GROWING CHF 20BN MARKET

PERFORM

IMPLANTOLOGY

>35% (+1%)
Market share

Market size
CHF 6.1BN

REGENERATIVES

<13%
Market share

Market size
CHF 1.3BN

TRANSFORM

CLEAR ALIGNER

<5%
Market share

Market size
CHF 4.9BN

DIGITAL EQUIPMENT

>10% (+5%)
Market share

Market size
CHF 1.8BN

CADCAM PROSTHETICS

<5%
Market share

Market size
CHF 5.7BN

Huge opportunities ahead in a CHF 20 bn addressable market

Source: Straumann Group estimates 2025

PERFORM – SUPPORTING IEXCEL MOMENTUM WITH INNOVATION

INNOVATION: NEW DIFFERENTIATED INNOVATIONS WILL ONLY BE AVAILABLE ON IEXCEL

- Launch of iGuide enabling guided surgery for full-arch treatments, expanding into high-value indications
- Continuous expansion with new prosthetic solutions with a new enhanced Variobase XC line including a laser treated surface
- New differentiated innovation strengthening differentiation and customer adoption

PERFORM – STRENGTHENING CLINICAL EDUCATION AND ENGAGEMENT

ITI: LEADING GLOBAL IMPLANTOLOGY NETWORK

- Global network for evidence-based education and research
- 25 000+ members across 100+ countries, training 200 000+ clinicians annually

AOMI: NEW GLOBAL SPECIALIST NETWORK

- Straumann supporting AOMI (Academy for Oral & Maxillofacial Implantology), newly launched network focused on advanced oral & maxillofacial implantology
- AOMI is bringing leading experts in complex procedures together

TRANSFORM – STRONG PROGRESS IN ORTHODONTICS TRANSFORMATION

INNOVATION: BOOSTED CLEARCORRECT VALUE PROPOSITION

- Integrated CBCT visualization strengthening treatment planning and differentiation
- Outcome simulation and automated case assessment improving patient communication and case acceptance
- Extended options with scalloped trimline – phased launch due to registrations
- RemoteCare enabling patient compliance and increased outcome consistency while reducing clinical appointments

CBCT visualization



ClearCorrect Outcome Simulator

TRANSFORM – VERY STRONG ADOPTION OF SIRIOS X3

SIRIOS X3
intraoral scanner

IOS PORTFOLIO – MULTI BRANDING & MULTI PRICING

Premium	3Shape TRIOS 5/6
Mid	SIRIOS X3
Entry	SIRIOS

- Strong IOS momentum thanks to new SIRIOS X3 driving growth of users on AXS could-based platform
- Expanded indications for Straumann Signature MIDAS 3D-printer

4

2026 OUTLOOK

– GUILLAUME DANIELLOT, GROUP CEO –

OUTLOOK 2026[1] – WELL- POSITIONED

- High-single digit organic revenue growth
- 30 to 60 basis points improvement of the core EBIT margin at constant 2025 exchange rates

- Expected volatility and regulatory environment to persist
- Resilient business model with strong market positions
- Highly engaged, entrepreneurial culture driving disciplined execution
- Significant growth opportunities in a CHF 20bn+ addressable market

[1] Barring unforeseen events

ANY QUESTIONS?

CALENDAR OF UPCOMING EVENT

2026	Event	Location
5-6 May	France & UK Roadshow – Jefferies	Paris, London
7 May	Italy Roadshow – Equita	Milan
26-27 May	Deutsche Bank European Champions Conference	Frankfurt
27-28 May	Stifel Jaws & Paws Conference	New York
9-10 Jun	Oddo Swiss Equity Conference	Interlaken
8-10 Jun	Goldman Sach Global Healthcare Conference	Miami
18 Jun	J.P. Morgan European MedTech Conference	London
23-25 Jun	Canada Roadshow – Kepler	Montreal, Toronto
30 Jun – 18 Aug	Quiet period	
19 Aug	Second quarter 2026 results	Webcast


THANK YOU.
straumanngroup